Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction

BJU International

Volumn 110, Issue , 2012, Pages

  Streng, Tomi ^a   Andersson, Karl Erik ^b   Hedlund, Petter ^c,d   Gratzke, Christian ^e   Baroni, Enrico ^f   D'Ambrosio, Daniele ^f   Benigni, Fabio ^c,f  

^a Turku University   (Finland)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d LINKÖPING UNIVERSITY   (Sweden)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f BioXell SpA   (Italy)

Author keywords

antimuscarinics; BXL628; partial urethral obstruction; vitamin D analogue

Indexed keywords

ELOCALCITOL; TOLTERODINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLADDER CAPACITY; BLADDER COMPLIANCE; BLADDER CONTRACTION; BLADDER FILLING; BLADDER PRESSURE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SCREENING; FEMALE; MICTURITION; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; RAT; TREATMENT DURATION; URETHRA OBSTRUCTION; URINARY FREQUENCY; URODYNAMICS;

ANIMALS; AREA UNDER CURVE; BENZHYDRYL COMPOUNDS; CALCITRIOL; CRESOLS; DRUG THERAPY, COMBINATION; FEMALE; INFUSIONS, INTRAVENOUS; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; URINARY BLADDER; URINARY BLADDER NECK OBSTRUCTION; URODYNAMICS; VITAMINS;

EID: 84863544214     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10838.x     Document Type: Article

References (31)

1. Emberton M, Zinner N, Michel MC, et al,. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk. BJU Int 2007; 100: 249-53
2. Andersson KE, Gratzke C,. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol 2007; 4: 368-78
3. Abrams P, Andersson KE, Birder L, et al,. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 2010; 29: 213-40
4. Hyman MJ, Groutz A, Blaivas JG,. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001; 166: 550-2
5. Andersson KE,. Storage and voiding symptoms: pathophysiologic aspects. Urology 2003; 62: (5 Suppl. 2): 3-10
6. Adorini L, Penna G, Fibbi B, Maggi M,. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. Ann N Y Acad Sci 2010; 1193: 146-52
7. Crescioli C, Ferruzzi P, Caporali A, et al,. Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog. Endocrinology 2003; 144: 3046-57
8. Crescioli C, Maggie M, Vannelli GB, et al,. Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia. J Clin Endocrinol Metab 2000; 85: 2576-83
9. Morelli A, Vignozzi L, Filippi S, et al,. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate 2007; 67: 234-47
10. Schroder A, Colli E, Maggi M, Andersson KE,. Effects of a vitamin D(3) analogue in a rat model of bladder outlet obstruction. BJU Int 2006; 98: 637-42
11. Crescioli C, Morelli A, Adorini L, et al,. Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab 2005; 90: 962-72
12. Colli E, Rigatti P, Montorsi F, et al,. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol 2006; 49: 82-6
13. Andersson KE,. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol 2011; 59: 377-86
14. Abrams P, Andersson KE,. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987-1006
15. Gratzke C, Streng T, Stief CG, et al,. Cannabinor, a selective cannabinoid-2 receptor agonist, improves bladder emptying in rats with partial urethral obstruction. J Urol 2011; 185: 731-6
16. Miyazato M, Sugaya K, Nishijima S, et al,. Changes of bladder activity and glycine levels in the lumbosacral cord after partial bladder outlet obstruction in rats. Int J Urol 2008; 15: 843-7
17. Lee SR, Hong CH, Choi YD, Kim JH,. Increased urinary nerve growth factor as a predictor of persistent detrusor overactivity after bladder outlet obstruction relief in a rat model. J Urol 2010; 183: 2440-4
18. Lee T, Hedlund P, Newgreen D, Andersson KE,. Urodynamic effects of a novel EP(1) receptor antagonist in normal rats and rats with bladder outlet obstruction. J Urol 2007; 177: 1562-7
19. Lee T, Andersson KE, Streng T, Hedlund P,. Simultaneous registration of intraabdominal and intravesical pressures during cystometry in conscious rats-effects of bladder outlet obstruction and intravesical PGE2. Neurourol Urodyn 2008; 27: 88-95
20. Graversen PH, Bagi P, Tofft HP, Colstrup H, Kristensen JK,. Pressure-to-cross-sectional area relationships in the proximal urethra of men with bladder outlet obstruction. J Urol 1996; 155: 267-70
21. Schafer W,. Analysis of bladder-outlet function with the linearized passive urethral resistance relation, linPURR, and a disease-specific approach for grading obstruction: from complex to simple. World J Urol 1995; 13: 47-58
22. Brading AF,. The physiology of the mammalian urinary outflow tract. Exp Physiol 1999; 84: 215-21
23. Tan AH, Gilling PJ, Kennett KM, et al,. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol 2003; 170 (4 Pt 1): 1270-4
24. Yamanishi T, Mizuno T, Tatsumiya K, et al,. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Neurourol Urodyn 2010; 29: 558-62
25. Andersson KE, Arner A,. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 2004; 84: 935-86
26. Rees RW, Foxwell NA, Ralph DJ, et al,. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 2003; 170 (6 Pt 1): 2517-22
27. Malmqvist U, Hedlund P, Sward K, Andersson KE,. Female pig urethral tone is dependent on Rho guanosine triphosphatases and Rho-associated kinase. J Urol 2004; 171: 1955-8
28. Penna G, Fibbi B, Amuchastegui S, et al,. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate 2009; 69: 480-93
29. Morelli A, Squecco R, Failli P, et al,. The vitamin D receptor agonist elocalcitol upregulates L-type calcium channel activity in human and rat bladder. Am J Physiol Cell Physiol 2008; 294: C1206-14
30. Chapple CR, Roehrborn CG,. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49: 651-8
31. Tiwari A,. Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility. IDrugs 2009; 12: 381-93